GLP-1 & compounded medication availability in Utah (2026)
Utah’s pharmacy regulators have addressed compounded semaglutide directly, in a written cautions-and-concerns piece in their May 2024 newsletter, backed by real citations from the state’s licensing division. Every one of those concerns targets a practice this service does not use, which is exactly why the detail is worth reading. All ten product lines we track are below, with the state’s own document cited.
What ships to Utah: all ten lines
| Product line | Available in Utah? | Typical delivery | Notes |
|---|---|---|---|
| GLP-1 (compounded semaglutide) | Yes | 8–10 business days | Base-form semaglutide, prescribed per patient. The practices Utah’s regulators flagged are cited below. |
| GLP-1/GIP (compounded tirzepatide) | Yes | 8–10 business days | Identical national pricing at each dose. |
| NAD+ | Yes | 8–10 business days | From licensed partner pharmacies. |
| Sermorelin | Yes | 8–10 business days | Longevity family; the ordering flow is the same. |
| Glutathione | No | N/A | Absent from the OrderlyMeds lineup today. |
| BPC-157 | Yes | 8–10 business days | Compounded injectable; federal facts directly below. |
| TB-500 | Yes | 8–10 business days | Compounded injectable, with its own section below. |
| KPV | No | N/A | Not carried, since peptide lines here are injectable-form only. |
| Epitalon | Yes | 8–10 business days | Compounded injectable; federal record below. |
| MOTS-c | Yes | 8–10 business days | Compounded injectable; read its separate federal entry below. |
A “No” is information, not an apology, and the matrix stays honest either way. Utah facts on this page were last reviewed on November 16, 2026.
Research peptides in Utah: BPC-157, TB-500, KPV, Epitalon & MOTS-c
Four of the five research-peptide lines ship to Utah: BPC-157, TB-500, Epitalon and MOTS-c, each a compounded injectable. KPV is not carried at all. Utah’s newsletter concerns, cited in the regulator section, were about semaglutide; the peptide sections below carry each line’s own federal record, stated identically in every state because the facts are federal.
BPC-157 in Utah
Utah addresses can receive BPC-157 as a compounded injectable on a patient-specific prescription, and the federal facts below travel with it.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed BPC-157 in Category 2, and BPC-157 has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense BPC-157 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
TB-500 in Utah
Dispensed to Utah as a compounded injectable under a patient-specific prescription; see its federal record below.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed TB-500 (thymosin beta-4 fragment) in Category 2, and TB-500 (thymosin beta-4 fragment) has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense TB-500 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
KPV in Utah
Not part of the formulary in Utah or any state: our peptide lines are injectable-form, and KPV is not.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed KPV in Category 2, and KPV has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense KPV pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
Epitalon in Utah
Carried for Utah as a compounded injectable. The federal picture below applies without a Utah-specific layer.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed Epitalon in Category 2, and Epitalon has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense Epitalon pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
MOTS-c in Utah
A compounded injectable for Utah orders, on a patient-specific prescription. Its federal record is stated on its own terms below.
FDA has evaluated MOTS-c as a bulk drug substance nominated for the section 503A bulks list and proposed that neither MOTS-c (free base) nor MOTS-c acetate be included on it, and MOTS-c has no FDA-approved indication. MOTS-c was formerly listed in Category 2 of FDA’s interim compounding policy, and it is no longer on that active list as of FDA’s April 22, 2026 update, because the nomination was withdrawn by the nominator. FDA’s record for the substance notes a potential immunogenicity concern by certain routes and no clinical data in humans, and FDA presented MOTS-c to its Pharmacy Compounding Advisory Committee in July 2026. Under the enforcement-discretion policy HHS published October 30, 2026 at 91 FR 68526, HHS does not intend to act against a state-licensed pharmacy, Federal facility, or licensed physician compounding MOTS-c under section 503A, limited to subcutaneous or intramuscular administration, under a valid patient-specific prescription, and subject to the policy’s other conditions, while rulemaking on the bulks list is pending. That policy does not add MOTS-c to the bulks list and does not make it an FDA-approved drug. Sources: FDA — bulk drug substances that may present significant safety risks (Category 2 and withdrawn nominations) · FDA — PCAC briefing document, July 23–24, 2026 (MOTS-c proposals, points 7–8) · HHS — 91 FR 68526, enforcement-discretion policy for 503A peptide compounding.
What Utah’s pharmacy regulators say about compounded semaglutide
Utah’s regulators wrote their concerns down, which makes this one of the rare state pages that can quote a primary document instead of inferring a stance. Three cited positions below.
In its May 2024 newsletter, the Utah Board of Pharmacy reported that the state’s Division of Professional Licensing had issued citations around compounded semaglutide on four concerns: unlicensed dispensing at medical spas, dispensing medical practitioners acting outside their dispensing rules, compounding with semaglutide salts (the salt formulations are not the FDA-approved version of semaglutide), and office-use compounding by 503A pharmacies. Source: Utah Board of Pharmacy — May 2024 newsletter (PDF, via NABP).
Pharmacy licensure in Utah runs through the Division of Professional Licensing, which licenses the pharmacy classes serving Utah patients — including standard pharmacies and remote dispensing pharmacies — under the state’s Pharmacy Practice Act. Source: Utah Division of Professional Licensing — Pharmacy.
Utah requires a prescriber to establish a provider-patient relationship and obtain the patient’s relevant clinical history before prescribing through telehealth, and does not accept a diagnosis, course of care, or prescription based solely on an online questionnaire, an email message, or a patient-generated history. Source: CCHP Policy Finder — Utah.
Every concern Utah’s regulators put in print maps to a practice this service does not use: no med-spa dispensing, no office-use compounding, no salt-form ingredients. Prescriptions are written per patient after a real evaluation, with the clinical history Utah expects, and filled by licensed pharmacies. That is the distinction the citations above draw, and it is worth reading in the newsletter’s own words.
Utah availability FAQs
Is compounded semaglutide available in Utah?
Yes, compounded per patient from the base form of semaglutide. The practices Utah's regulators cited (salt forms, office-use compounding, med-spa dispensing) are not how OrderlyMeds works.
Does an online questionnaire count as an evaluation in Utah?
No. Utah expects a provider-patient relationship and a relevant clinical history before a telehealth prescription, and a questionnaire or email alone does not qualify. The cited regulator section carries the detail.
Can I get BPC-157 or other research peptides shipped to Utah?
Four of the five ship to Utah as compounded injectables under patient-specific prescriptions: BPC-157, TB-500, Epitalon and MOTS-c. KPV does not. Each section above states that line's own federal record.
How long does delivery to Utah take?
The published window is 8–10 business days from signup, statewide.
Keep exploring
Ready when you are
See if you’re eligible
Compounded semaglutide from $74/month for your first 2 months — provider visit, medication, syringes, and shipping all included, at the same price for every dose. No membership fees.
Check eligibilitySecure. Private. No commitment
